| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Ibrutinib |
| Brand | Imbruvica® |
| Indication | For the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This indication is an extension to the original licence in the relapsed/refractory setting. |
| Assessment Process | |
| Rapid review commissioned | 02/08/2016 |
| Rapid review completed | 24/08/2016 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
Not considered cost-effective due to non-submission of full pharmacoeconomic assessment.